Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | P-CD19CD20-ALLO1 |
| Trade Name | |
| Synonyms | P-CD19CD20-ALLO-1|P-CD19CD20-ALLO 1 |
| Drug Descriptions |
P-CD19CD20-ALLO1 are allogeneic T stem cell-rich T-lymphocytes engineered to express chimeric antigen receptors (CARs) targeting CD19 and CD20, which potentially induces antitumor activity against CD19 and CD20-expressing tumor cells (Blood (2024) 144 (Supplement 1): 4805). |
| DrugClasses | CD19 Immune Cell Therapy 72 CD20 Immune Cell Therapy 14 |
| CAS Registry Number | NA |
| NCIT ID | C201791 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| P-CD19CD20-ALLO1 | P-CD19CD20-ALLO1 | 0 | 1 |